Gyre Therapeutics
GYRE
56 hedge funds and large institutions have $236M invested in Gyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 7 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 2
496% more capital invested
Capital invested by funds: $39.7M → $236M (+$197M)
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
60% more funds holding
Funds holding: 35 → 56 (+21)
3.61% more ownership
Funds ownership: 6.66% → 10.27% (+3.6%)
55% less call options, than puts
Call options by funds: $2.29M | Put options by funds: $5.15M
Top Buyers
| 1 |
SCM
Sio Capital Management
New York
|
+$23.6M |
| 2 |
DM
Deerfield Management
New York
|
+$20.7M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$17.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$15.5M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.8M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NIT
51
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| $3K | +$2.42K | +13 | New |
|
|
IP
52
Intellectus Partners
San Francisco,
California
| $2K | – | – | – |
|
|
PAM
53
Panagora Asset Management
Boston,
Massachusetts
| $2K | – | – | – |
|
|
EA
54
Edge Advisors
Atlanta,
Georgia
| $1K | – | – | – |
|
|
PVI
55
Pura Vida Investments
New York
| – | -$818K | -8,000 | Closed |
|
|
RJA
56
Raymond James & Associates
St Petersburg,
Florida
| – | -$585K | -5,719 | Closed |
|
|
AAP
57
Ardsley Advisory Partners
Stamford,
Connecticut
| – | -$205K | -2,000 | Closed |
|
|
KM
58
Kalos Management
Alpharetta,
Georgia
| – | -$222K | -1,613 | Closed |
|
|
DS
59
DRW Securities
Chicago,
Illinois
| – | -$164K | -1,600 | Closed |
|
|
FPF
60
FNY Partners Fund
New York
| – | -$13K | -133 | Closed |
|
61
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -80 | Closed |
|
GYRE Hedge Fund Activity: Q1 2018 in Review
56 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2018, worth a combined $236M — up 496% from $39.7M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GYRE positions and 7 closed out — a net gain of 21 holders — while 18 added to existing stakes and 2 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $23.6M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $818K sold.
- 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2018, up from 35 in Q4 2017.
- Funds reported $236M of Gyre Therapeutics stock for Q1 2018, up 496% quarter-over-quarter.
- 28 funds opened new Gyre Therapeutics positions in Q1 2018 and 7 closed out, a net change of +21 holders.
- The largest Gyre Therapeutics buyer in Q1 2018 was Sio Capital Management, an estimated $23.6M added.
- The largest Gyre Therapeutics seller in Q1 2018 was Pura Vida Investments, an estimated $818K sold.
Based on aggregated 13F filings for Q1 2018.